WallStreetZenWallStreetZen

NASDAQ: APVO
Aptevo Therapeutics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Be the first to know when Wall Street analysts revise their APVO stock forecasts and price targets.

Forecast return on equity

Is APVO forecast to generate an efficient return?

Company
-148.24%
Industry
252.48%
Market
228.08%
APVO's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is APVO forecast to generate an efficient return on assets?

Company
-95.5%
Industry
90.65%
APVO is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

APVO earnings per share forecast

What is APVO's earnings per share in the next 3 years based on estimates from 3 analysts?

Avg 1 year Forecast
-$5.49-100.29%
Avg 2 year Forecast
-$1.63-100.09%
Avg 3 year Forecast
-$1.58-100.08%

APVO revenue forecast

What is APVO's revenue in the next 3 years based on estimates from 3 analysts?

Avg 1 year Forecast
$0.0
Avg 2 year Forecast
$0.0
Avg 3 year Forecast
$0.0

APVO vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
APVO$1.13N/AN/A
CTXR$1.12$6.00+435.71%Strong Buy
GDTC$1.66N/AN/A
PMN$8.99$71.50+695.33%Strong Buy
TRAW$2.33$8.00+243.35%Buy
View Top Biotech Stocks

Aptevo Therapeutics Stock Forecast FAQ

What is APVO's earnings growth forecast for 2025-2027?

(NASDAQ: APVO) Aptevo Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 43.76%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 42.65%.

Aptevo Therapeutics's earnings in 2025 is -$27,952,000.On average, 3 Wall Street analysts forecast APVO's earnings for 2025 to be -$92,468,771, with the lowest APVO earnings forecast at -$88,842,545, and the highest APVO earnings forecast at -$95,188,441. On average, 3 Wall Street analysts forecast APVO's earnings for 2026 to be -$27,500,006, with the lowest APVO earnings forecast at -$26,421,575, and the highest APVO earnings forecast at -$28,308,830.

In 2027, APVO is forecast to generate -$26,640,631 in earnings, with the lowest earnings forecast at -$25,595,900 and the highest earnings forecast at -$27,424,179.

If you're new to stock investing, here's how to buy Aptevo Therapeutics stock.

What is APVO's revenue growth forecast for 2025-2027?

(NASDAQ: APVO) Aptevo Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 101.28%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 25.62%.

Aptevo Therapeutics's revenue in 2025 is $0.On average, 3 Wall Street analysts forecast APVO's revenue for 2025 to be $0, with the lowest APVO revenue forecast at $0, and the highest APVO revenue forecast at $0. On average, 3 Wall Street analysts forecast APVO's revenue for 2026 to be $0, with the lowest APVO revenue forecast at $0, and the highest APVO revenue forecast at $0.

In 2027, APVO is forecast to generate $0 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $0.

What is APVO's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: APVO) forecast ROA is -95.5%, which is lower than the forecast US Biotechnology industry average of 90.65%.

What is APVO's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: APVO) Aptevo Therapeutics's current Earnings Per Share (EPS) is $1,860.37. On average, analysts forecast that APVO's EPS will be -$5.49 for 2025, with the lowest EPS forecast at -$5.27, and the highest EPS forecast at -$5.65. On average, analysts forecast that APVO's EPS will be -$1.63 for 2026, with the lowest EPS forecast at -$1.57, and the highest EPS forecast at -$1.68. In 2027, APVO's EPS is forecast to hit -$1.58 (min: -$1.52, max: -$1.63).

What is APVO's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: APVO) forecast ROE is -148.24%, which is considered weak.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.